Babak J. Orandi

1 month ago | healio.com | Jill Rollet |Richard Smith |Babak J. Orandi

Key takeaways: Kidney transplant recipients with type 2 diabetes prescribed GLP-1 receptor agonists had 31% lower mortality vs. nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of graft loss. For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with improved long-term graft survival and overall survival, according to study data. In a retrospective cohort study, Babak J.